Comparative Anthelmintic Activity of Strategic Sustained Low-level Administration of Albendazole in Feed Pellets Compared to Single Doses of Closantel and Tetramisole against Natural Ovine Parasitic Gastroenteritis

The strategic use of single therapeutic doses of closantel, tetramisole or sustained low-level administration of albendazole in feed pellets in controlling naturally acquired parasitic gastroenteritis in sheep was investigated on a farm in semi-arid Rajasthan, India. A total of 303 5- to 6-month-old sheep were divided into three groups. Two groups were dosed with single therapeutic doses of closantel and tetramisole and the third group was given a low-level medication with albendazole through feed pellets for 30 days. Faecal egg counts revealed significantly lower counts (p<0.001) in the group treated with closantel compared to the other two groups. The faecal egg counts in the group receiving sustained low-level albendazole rose after withdrawal of the medication but remained significantly lower than those in the group treated with tetramisole up to 7 weeks after treatment (p<0.05). On the other hand, in the group treated with tetramisole, the mean faecal egg count rose from 3 weeks after treatment and remained continuously higher than those in any other group up to 12 weeks after treatment. The closantel-treated group gained more body weight but the first six-monthly greasy fleece yield was greater in the group treated with medicated pellets. During the first 3 months of the experiment, three animals in the group treated with tetramisole died of parasitic gastroenteritis. Following sustained low-level administration of albendazole in feed pellets, the plasma disposition curve of both the sulphoxide and sulphone metabolites reached its plateau level by day 5 and remained almost constant thereafter. The comparative cost-effectiveness of the three treatment regimes during the first 3 months of treatment was best for the group treated with closantel followed by the group treated with medicated feed pellets.     

Interindividual variability in plasma concentrations after systemic exposure of swine to dietary doxycycline supplied with and without paracetamol: a population pharmacokinetic approach

Anorexigenic substances released during infection may hinder the therapeutic efficacy of in-feed antibiotics. Paracetamol (acetaminophen; PARA) inhibits the anorexia of infection and seems to improve the clinical efficacy of doxycycline (DOX) against bacterial respiratory disease in swine herds. In order to verify whether PARA selectively stimulates intake of DOX-medicated feed in diseased pigs, we documented the pharmacokinetics (PK) of DOX when coadministered with PARA and examined the effect of in-feed PARA on the interindividual variability in plasma concentrations after systemic exposure to in-feed DOX in swine herds with respiratory disease. Systemic exposure to DOX was measured with the area under the curve (AUC) of its plasma concentrations over time. First, a rich-sampling PK study of in-feed and i.v. DOX (10 mg/kg of BW) and PARA (30 and 10 mg/kg of BW, respectively) was performed on 5 pigs. The PK profiles of in-feed DOX were used in mathematical simulations to determine 5 optimal sampling times for the farm-based population PK study. A randomized, blind, parallel PK study was performed in 2 herds with bacterial respiratory disease, where liquid feed was fortified with DOX alone (5 mg x kg of BW(-1) x meal(-1)) or combined with PARA (15 mg x kg of BW(-1) x meal(-1)). Medicated meals were given twice, 12 h apart, to group-housed growing pigs (n > 50 pigs x treatment(-1) x herd(-1), totaling 215 pigs). Plasma concentrations of DOX and PARA were measured with HPLC. At variance with our expectations, PARA decreased (P = 0.069) mean AUC of in-feed DOX and did not decrease its variability (P > 0.34). Mean AUC of DOX increased with feed intake and with initial exposure to DOX, and was greater in sick animals. Therefore, symptomatic PARA-induced improvement in bacterial respiratory disease control with DOX is more likely caused by its analgesic/antipyretic effects than by its orexigenic effect. Interindividual variation in the AUC of DOX was large in pigs given group medication, even when sufficient feeding space was allowed and the amount of feed offered was greater than their requirements. Therefore, future studies to improve the efficacy of group antibiotic therapy should focus on feeding behavior characteristics as well as biopharmaceutical properties of medicated feeds.     

Efficacy of an albendazole feed formulation against bovine gastrointestinal nematodes including arrested larvae of Ostertagia ostertagi

The efficacy of an albendazole feed premix formulation was compared with that of an albendazole drench suspension for control of gastrointestinal nematodes in 31 beef cattle. The premix (11 cattle) and drench suspension (9 cattle) were found to have similar efficacies at a dosage of 7.5 mg/kg of body weight. When compared with controls (11 cattle), both formulations caused significant (P less than 0.05) reductions in worm counts with an efficacy of 98% or greater against adult Haemonchus placei, Ostertagia ostertagi, Trichostrongylus axei, Cooperia punctata, and C pectinata. There was no significant effect against arrested 4th-stage larvae of O ostertagi. Adverse effects of albendazole treatment were not observed, and the premix formulation was readily consumed by cattle.     

Increased bioavailability of tylosin phosphate as in-feed medication formulated for long-action pellets in broiler chickens

Circadian variation of serum concentrations of tylosin in broiler chickens after in-feed medication prompted a comparison study of the serum profiles of this drug after in-feed medication with standard tylosin phosphate (Tprf reference formulation group), and after in-feed medication with a sustained-release pellet formulation (Tpsr group), based on Patent No.MX/a/2012/013222 and PCT/MX2013/000137, in broiler chickens. Six hundred 4-week-old Ross broiler chickens were in-feed medicated with tylosin phosphate at an approximate dose of 25.2 mg/kg/d, based on daily feed consumption values and a final concentration of tylosin in feed of 200 mg/kg of feed. Approximately 2 to 3 mL of blood were obtained per 5 chickens every 2 h, avoiding the sampling of a bird more than once and during 72 h after making medicated feed available for the first time. Serum concentrations of tylosin were determined by HPLC. Gaussian multi-peak regressions were then fitted to serum concentration vs. time profiles. Day by d areas under the serum concentration vs. time profiles (AUC_0–24), as well as overall AUC_0–72, were statistically higher for the Tpsr group (P < 0.001). Also, maximum serum concentrations obtained and relative bioavailability for the Tpsr formulation were statistically higher (382.8%) as compared to the Tprf group (P < 0.01). Considering the referred improved values of AUC observed in the Tpsr formulation, as well as the fact that tylosin is a time-dependent antibacterial drug, better clinical responses are postulated with this pharmaceutical preparation intended for chickens. Tissue deposition studies for this new formulation of tylosin are required.     

The effects of pelleting and glucanase supplementation in hulled barley based diets on feed manufacture,broiler performance,and digesta viscosity

Feeding broilers barley-based diets requires special consideration primarily due to effects on increased digesta viscosity and decreased nutrient digestion. Pelleting and glucanase supplementation are commonly performed prior to feeding broilers barley-based diets; however, the interaction of these practices is complex. The objective of this study was to establish a comprehensive evaluation of glucanase efficacy including: degree of processing, activity postpelleting, broiler performance, and digesta viscosity. Treatments were arranged in a 5 (diet formulation) × 2 (processing) factorial in a randomized complete block design with 8 replications/treatment. The 5 diet formulations consisted of positive control (PC), negative control (NC), glucanase A (GA) 125 or 1,000 β-Glu-U/kg feed, and glucanase B (GB) 1,000 β-Glu-U/kg feed. The PC and NC diets differed in metabolizable energy by 150 kcal/kg and enzymes were added to NC formulations. Diets were either fed as unprocessed mash or ground pellets. Diet formulation × processing did not interact for feed intake (FI), FCR, or total tract viscosity (P > 0.05); however, a trend was observed for ending bird weight, demonstrating that for ground pellets, GA 1,000 β-Glu-U/kg feed was improved relative to NC and similar to PC (P = 0.0903). Benefits associated with GB were not of similar magnitude, perhaps in part due to a 50% decrease in activity postpelleting. In addition, GA benefits were not suggested for unprocessed mash. The main effect processing was significant (P < 0.0001) demonstrating that broilers fed ground pellets resulted in greater pen ending bird weight, FI, and bird live weight gain (LWG) compared to birds fed unprocessed mash diets. Evaluations of glucanase should go beyond in vitro activity and include live bird performance using feed that has undergone pelleting.     

Critical test evaluation of butamisole against gastrointestinal parasites of horses and ponies.

A critical test was performed to evaluate the anthelmintic properties of an injectable butamisole formulation and to compare the efficiency with that of a commercially available piperazine-thiabendazole anthelmintic. The test was done in 10 horses and 15 ponies with naturally acquired parasitic infections. Butamisole was administered at the dose level of 2.5 or 3.75 mg/kg of body weight by either subcutaneous or deep intramuscular injection. Given at the dose level of 2.5 mg/kg, butamisole was highly effective (99%) against Strongylus vulgaris and moderately effective (49%) against Parascaris equorum. At the 3.75 mg/kg dose rate, butamisole was highly effective against both S vulgaris (97%) and P equorum (94%). Butamisole had limited efficacy against other parasite species. Signs of toxicosis, long-term swelling of the injection sites, or tissue damage were not seen after injection.     

First experience on the effect of in-feed lincomycin for the control of proliferative enteropathy in growing pigs

This trial's aim was to evaluate the effect of in-feed lincomycin for the control of proliferative enteropathy (PE; also known as ileitis) in growing pigs, in which it is associated with significant morbidity levels. Investigation regarding the efficacy of this substance in growing pigs has never been carried out before in a field trial. The trial farm had a previous history of PE outbreaks. On day 1 of the trial (age of 62 +/- 1.5 days), 240 pigs were divided into two groups of 120 pigs/group which were allocated into five pens of 24 pigs each. Therefore, a randomized block design was used with two experimental groups (T1-T2) and five replicates (pens) per group. T1 group served as negative control (NC) animals which were receiving no medication and conversely T2 group received in-feed lincomycin at the dose of 110 mg/kg of feed. The treatment period lasted for 3 weeks, followed by an observation period of 4 weeks up to the age of 111 +/- 1.5 days which was the end of the grower stage. Administration of lincomycin at a dose of 110 mg/kg of feed had beneficial effects compared with the NC group. The pigs of T2 group showed significant improvement of their production parameters in terms of average daily body gain (ADG) and feed conversion ratio (FCR) not only during the treatment period (ADG: 0.515 +/- 0.050 versus 0.481 +/- 0.071 and FCR: 2.38 +/- 0.05 versus 2.56 +/- 0.08, for T2 and T1 groups respectively), but also during the remaining period until the end of the grower stage (observation period: ADG: 0.687 +/- 0.019 versus 0.646 +/- 0.044 and FCR: 2.58 +/- 0.02 versus 2.74 +/- 0.02 respectively). Other effects in the T2 group refer to the reduction of diarrhoea prevalence (mean pen diarrhoea score during the whole grower stage: 0.200 +/- 0.060 versus 0.632 +/- 0.041 respectively), morbidity rates (morbidity rates during the whole grower stage: 15.83% versus 45.00% respectively) and the reduction of Lawsonia intracellularis prevalence as shown by polymerase chain reaction diagnostic method (at the end of the treatment period: 10.0% versus 60.0% respectively). In conclusion, treatment with 110 mg lincomycin/kg of feed for 21 consecutive days had a beneficial effect on the control of PE in growing pigs.     

Efficacy of slow-release albendazole capsules in controlling lungworms and gastro-intestinal nematodes in red deer (Cervus elaphus)

One hundred and fifteen young red deer (Cervus elaphus), heavily infected with lungworm (Dictyocaulus viviparus) and lightly infected with gastro-intestinal nematodes, were divided into three groups. One group of 50 animals was treated with one adult sheep dose of a slow-release albendazole capsule, another group of 50 was dosed orally five times with liquid albendazole and 15 were left as untreated controls. The capsule eliminated faecal lungworm larvae during the 103-day trial period. There was a highly significant difference in faecal larval counts between the capsule-treated and control group. Over the trial period, the mean body weight gain of the untreated, liquid albendazole and capsule-treated animals was 0.1 kg, 4.5 kg and 7.8 kg respectively.     

Efficacy of an in-feed ivermectin formulation against gastrointestinal helminths, lungworms, and sarcoptic mites in swine

The efficacy of ivermectin as an in-feed formulation was evaluated against naturally acquired gastrointestinal helminths, lungworms, and sarcoptic mites (experiment 1; n = 24) and against induced infection with intestinal nematodes (experiment 2; n = 24) in pigs. Treatments consisted of ivermectin administered in feed at concentrations calculated to provide 100 or 200 micrograms/kg of body weight/d for 7 days or of nonmedicated feed (controls) for 7 days. At concentration of 100 micrograms of ivermectin/kg/d, efficacy against naturally acquired infections was 97.7% for Ascaris suum, 97.8% for Metastrongylus spp, greater than 99% for Oesophagostomum spp, 100% for Macracanthorhynchus hirudinaceus, and 89.7% for Ascarops strongylina. Against induced infections (fourth-stage larvae), efficacy was 100% for A suum and 96.9% for Oesophagostomum spp. At concentration of 200 micrograms of ivermectin/kg/d, efficacy against naturally acquired infections was 100% for A suum, Hyostrongylus rubidus, Metastrongylus spp, and Ascarops strongylina; greater than 99% for Oesophagostomum spp; and 85.9% for Macracanthorhynchus hirudinaceus. Against induced infections (fourth-stage larvae), efficacy was 100% for A suum and 95% for Oesophagostomum spp. At concentrations of 100 and 200 micrograms of ivermectin/kg/d, efficacy against Sarcoptes scabiei var suis was evidenced by elimination of the mite by posttreatment day 14.     

Efficacy of albendazole against nematode parasites isolated from a goat farm in Ethiopia: relationship between dose and efficacy in goats

A suspected case of albendazole resistance in a goat farm of Hawassa University was examined using faecal egg count reduction test (FECRT), controlled anthelmintic efficacy test and egg hatch assay (EHA) to verify the development of resistance and/or the need for higher doses of the drug in goats than in sheep. The experiment was conducted in 12 sheep (2 groups: treatment versus control) and 24 goats (4 groups: 3 treatments versus control, n = 6; per group) following artificial infection with infective larvae of Haemonchus contortus and Oesophagostomum columbianum. The first group of sheep and goats were treated orally with albendazole at the dose rate of 3.8 mg/kg body weight (i.e. manufacturer's recommended dose for sheep) while the second group of sheep and the fourth group of goats were left untreated. The second and the third group of goats were treated with albendazole at 5.7 and 7.6 mg/kg respectively. The FECRT showed an efficacy of albendazole in goats to be 65.5, 81.4 and 84.1% at the dose rate of 3.8, 5.7 and 7.6 mg/kg body weight respectively while in sheep it was 62% at the dose rate of 3.8 mg/kg. Increasing the dose to 1.5 the sheep recommended dose induced minor improvement of efficacy in goats; however the efficacy was almost the same at 1.5 and twice the dose recommended for sheep. Worm counts at day 15 post-treatment revealed that H. contortus has developed resistance to albendazole. EHA results also supported these findings. On the other hand, O. columbianum was 100% susceptible at all dose levels tested.     

Efficacy of slow-release albendazole capsules in controlling lungworms and gastro-intestinal nematodes in red deer (Cervus elaphus)

One hundred and fifteen young red deer (Cervus elaphus), heavily infected with lungworm (Dictyocaulus viviparus) and lightly infected with gastro-intestinal nematodes, were divided into three groups. One group of 50 animals was treated with one adult sheep dose of a slow-release albendazole capsule, another group of 50 was dosed orally five times with liquid albendazole and 15 were left as untreated controls. The capsule eliminated faecal lungworm larvae during the 103-day trial period There was a highly significant difference in faecal larval counts between the capsule-treated and control group. Over the trial period, the mean body weight gain of the untreated, liquid albendazole and capsule-treated animals was 0.1 kg, 4.5 kg and 7.8 kg respectively.     

Eprinomectin pour-on for control of Boophilus microplus (Canestrini) ticks (Acari: Ixodidae) on cattle

The efficacy of a commercial pour-on formulation of eprinomectin, a macrocyclic lactone, against experimental infestations of Boophilus microplus (Canestrini) ticks was evaluated in two trials involving 27 Bos taurus calves. The first trial was designed to evaluate the effects of a single treatment at a dose of 0.5 mg/kg of body weight against standard size B. microplus females (4.5-8.0 mm long). A significant reduction in tick numbers (P<0.05, Wilcoxon test) was observed between treated calves as compared to untreated ones from Day 3 (44% efficacy) after treatment to the end of the trial on Day 28 (96.9%), with a peak efficacy of 97.1% on Day 21. In the second trial the effect of eprinomectin on standard size tick numbers, engorgement weight and fertility of female ticks from calves with a single treatment dose of 1 mg/kg on Day 0 and calves treated twice at a dose of 0.5 mg/kg on Days 0 and 4 was evaluated. An efficacy >93% was obtained from Day 2 to Day 28 after treatment in calves treated twice at 0.5 mg/kg, and to the end of the trial (Day 35) in calves treated once with 1 mg/kg. The 1mg/kg treatment provided >98% residual efficacy for at least 7 days. During the first part of the second trial the efficacy of eprinomectin resulted from a dramatic adverse effect on engorgement weight and fertility of female ticks, with 100% control on Day 5 (dosage of 1 mg/kg) and on Days 6 and 7 (two doses of 0.5 mg/kg). Following Day 7, most of the effect was due to reduction in the number of standard size female ticks.     

Therapeutic and prophylactic efficacy of milbemycin oxime (Interceptor) against Thelazia callipaeda in naturally exposed dogs

Two trials were conducted to evaluate the therapeutic and prophylactic activity of milbemycin oxime (Interceptor, Novartis Animal Health) against the eye-worm Thelazia callipaeda (Spirurida, Thelaziidae) infection. In Trial 1, the therapeutic efficacy of milbemycin oxime was evaluated in 55 naturally infected dogs treated with min. 0.5mg/kg milbemycin oxime. The dogs were clinically examined for the presence of eyeworms before and again 7 days after treatment. Dogs still positive were given a second treatment and re-checked again a week later. Forty-eight of the 55 dogs tested negative 1 week after treatment (87.3% reduction of infection rate). Following the second treatment 6 of these 7 dogs tested negative 1 week later resulting, after two treatments, in a reduction of infection rate of 98.2%. In Trial 2, the prophylactic efficacy of milbemycin oxime was evaluated in 60 uninfected dogs. Thirty dogs were treated with milbemycin oxime monthly from June to November with the recommended dose rate for the prevention of heartworm disease (> or =0.5mg/kg), 30 dogs served as untreated controls. At the end of the trail 1 dog in the treated group and 10 dogs in the control group became infected during the trial. The incidence of infection differed significantly between treated and control dogs (p=0.0056). The efficacy of the prophylactic use of a monthly treatment with milbemycin oxime showed 90% efficacy in reducing T. callipaeda infection rate.     

Studies of the tolerance and toxicity of Luzern-green-meal pellets after selenium fertilization

In a feeding trial, rabbits allotted in 3 experimental groups were fed rations containing 2.09, 9.83 and 19.5 mg selenium/kg feed in the form of selenium-enriched alfalfa green meal pellets. The selenium enrichment was done by foliar application (spraying) of the 20--25 cm high plant stand with 2.5 kg SeO2 per hectare in watery solution. The control animals were given normal alfalfa green meal pellets of 0.16 ppm selenium content. Toxicity and lethality, tolerance limit and nutritive effect of the pellets were studied. Plant-assimilated selenium was found to be converted more efficiently by the animal organism than was selenium from inorganic compounds (higher retention rate, better gain in body weight and lower feed expenditure). Therefore, the selenium supply to farm animals should be improved by feeding crops that were given selenium dressings.     

Prevention of pleuropneumonia in pigs by in-feed medication with sulphadimethoxine and sulphamethoxazole in combination with trimethoprim

The prophylactic effect of in-feed medication of conventional pigs with sulphadimethoxine (SDM), sulphamethoxazole (SMX), and trimethoprim (TMP) was tested by using an Actinobacillus pleuropneumoniae infection model. In each of five experiments, six pigs were given medicated feed twice daily and three pigs received antibiotic-free feed and served as positive (unmedicated, infected) controls. The following drugs or drug combinations were tested (in mg per kg feed): 500 SDM + 100 TMP, 500 SMX + 100 TMP, 125 SMX + 25 TMP, 125 SMX (alone) and 25 TMP (alone). After six days of feed medication, all animals were endobronchially inoculated with A. pleuropneumoniae in a dose of 1-3.10(4) colony-forming units (CFU). The response to the challenge in all control pigs was characterized by fever, lethargy, anorexia, reduced water consumption, and laboured breathing. At autopsy all controls manifested a fibrinous haemorrhagic pleuropneumonia. In-feed medication with 500 SDM + 100 TMP, 500 SMX + 100 TMP as well as 125 SMX + 25 TMP resulted in an effective protection against the challenge in all treated animals. After consumption of feed medicated with 125 mg per kg SMX or 25 mg per kg TMP, pleuropneumonia was evident in all challenged pigs. The results of this study indicate an in vivo potentiation of SMX and TMP in pigs against this respiratory tract pathogen.     

The effect of continuous in-feed medication with thiophanate on Ascaris suum and Oesophagostomum spp. egg output in young pigs

The full potential of anthelmintics now available for single dose treatment is not achieved because the devising system for worm control in piglets/weaners is not efficiently applicable in practice. Therefore an in-feed medication programme for growing young pigs, allowing only one feed lot to be handled by the farmer, was tested in two studies. Study A Feed containing 0.0225% thiophanate was continuously fed almost ad lib. to piglets from birth right up to about 25 kg body weight when ready for fattening. This control measure effectively prevented A. suum and Oesophagostomum from becoming established during the whole pre-fattening period, thus allowing "worm-free" weaners to be produced. -33% of animals receiving unmedicated feed harboured mature Oesophagostomum already at an age of 63 days when first examined. Three out of 97 unmedicated pigs were then A. suum egg-count positive. At the same time all medicated pigs, except one with a low Oesophagostomum egg output, were egg-count negative. All medicated were still egg-count negative at 23-29 days after the withdrawal of the feed. About 30% of unmedicated pigs were then shedding eggs of A. suum and Oesophagostomum respectively. At 45-49 days after the withdrawal of the medicated feed 8% of previously medicated pigs and 43% of unmedicated pigs were A. suum egg-count positive. The corresponding figures for Oesophagostomum egg-count positive pigs were 6% and 40% respectively. The acquisition of worm infections by previously medicated pigs most probably was made in the fattening unit after the withdrawal of the thiophanate medicated feed. Study B In this study it was further substantiated that in-feed medication of pigs with thiophanate prevents A. suum from becoming established. All treated pigs were A. suum egg-count negative at Day 43 and 46 after the withdrawal of the medicated feed whereas about 62% of untreated control pigs were shedding A. suum eggs at the same time. This finding justify the proposal that the in-feed medication performed prevented larval migration. Furthermore it was shown that the in-feed medication must proceed right up to the transfer of piglets to the fattening unit in order to achieve its full potential. Farrowing pens may be heavily contaminated with infective Oesophagostomum larvae at the end of the pre-fattening period resulting in sudden and heavy nodular worm infections after the withdrawal of the medicated feed.     

Efficacy of clorsulon and albendazole against Fascioloides magna in naturally infected white-tailed deer

The efficacy of clorsulon and of albendazole against Fascioloides magna were evaluated in 36 naturally infected white-tailed deer (Odocoileus virginianus) in southern Texas. A single oral dose of clorsulon suspension (12 to 30 mg/kg of body weight; mean = 24 mg/kg) was given to each deer and killed 153 (92%) of 167 mature flukes and 4 (80%) of 5 immature flukes recovered at necropsy. A single oral dose of albendazole paste (17 to 46 mg/kg; mean = 26 mg/kg) was given to each deer and killed 148 (89%) of 167 mature flukes and 4 (67%) of 6 immature flukes recovered at necropsy. In 82 nontreated control deer, 271 live flukes were recovered; dead flukes were not recovered.     

A review of the use of a controlled-release formulation of ivermectin in the treatment and prophylaxis of Psoroptes ovis infestations in sheep.

The options for the treatment and control of sheep scab (psoroptic mange) have been increased in recent years through the introduction of the endectocides ivermectin, doramectin and moxidectin. Whilst therapeutic efficacy is good, the current injectable formulations offer limited protection against re-infestation with Psoroptes ovis. An intraruminal controlled-release formulation of ivermectin has been developed to provide therapeutic and prophylactic activity against a range of sensitive endo- and ecto-parasites of sheep for 100 days after administration. These ivermectin boluses are designed to release ivermectin at 20-40 microg/kg/day over 100 days and were developed for use in sheep of 20-90 kg bodyweight. Several controlled therapeutic and prophylactic trials against sheep scab have been conducted under a variety of protocols with such boluses in Europe and South America. The results of these studies indicate that the bolus provides 100% therapeutic efficacy against established P. ovis infestations and equivalent prophylactic efficacy against challenge infestations administered during the active life of the bolus.     

The effect of josamycine on the control of ileitis in weaned piglets under field conditions

The aim of this trial was to evaluate the effect of in-feed josamycine on the control of ileitis in weaned piglets. On a farm with a previous history of ileitis outbreaks, 288 piglets at weaning age (25 +/- 2 days old) were allocated into three experimental groups, each group comprising of four pens with 24 piglets in each pen. Group one (T1) served the trial as negative control group (unmedicated), group T2 was administered josamycine at 36 mg/kg of feed and group T3 was administered josamycine at 50 mg/kg of feed. Treatments lasted for 14 days followed by an observation period of 28 days. Administration of josamycine at both inclusion levels tested had a beneficial effect compared with the negative control group, by the reduction of prevalence of diarrhoea, the enhancement of growth performance and the reduction of prevalence of Lawsonia intracellularis in the intestine, as determined either by the PCR method or by specific histopathological examinations. The beneficial effect of josamycine was more pronounced at the inclusion level of 50 mg/kg of feed.     

米尔贝肟片对犬血液学指标和肝肾功能的影响

为了评价米尔贝肟片对犬的安全性,将24只本地健康杂种犬,随机分为4组,分别按0.5、1.5、2.5、5.0 mg/kg剂量（相当于临床推荐剂量的1、3、5、10倍）食喂米尔贝肟片,连续给药3d。在用药前（0 d）和用药后1、3、7、14 d测定其体温、体重、血常规及肝肾功能指标。结果表明,与给药前相比,4种剂量的米尔贝肟片对犬的血常规及肝肾功能指标无显著影响,且动物体温、体重及临床表现均正常。说明米尔贝肟片在试验剂量下对犬的血液学和肝肾功能没有影响。